Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S230-S230
- Garcia-Manero, Guillermo
- Wei, Andrew H.
- Porkka, Kimmo
- Knapper, Steve
- Traer, Elie
- Scholl, Sebastian
- Vey, Norbert
- Wermke, Martin
- Janssen, Jeroen
- Narayan, Rupa
- Loo, Sun
- Tovar, Natalia
- Kontro, Mika
- Ottmann, Oliver
- Naidu, Purushotham
- Orlando, Elena
- Patel, Nidhi
- Makofske, Jessica
- Ma, Fei
- Zhang, Na
- Mohammed, Anisa
- Rinne, Mikael L.
- Borate, Uma
- Brunner, Andrew M.
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Garcia-Manero, Guillermo
- Wei, Andrew H.
- Porkka, Kimmo
- Knapper, Steve
- Traer, Elie
- Scholl, Sebastian
- Vey, Norbert
- Wermke, Martin
- Janssen, Jeroen
- Narayan, Rupa
- Loo, Sun
- Tovar, Natalia
- Kontro, Mika
- Ottmann, Oliver
- Naidu, Purushotham
- Orlando, Elena
- Patel, Nidhi
- Makofske, Jessica
- Ma, Fei
- Zhang, Na
- Mohammed, Anisa
- Rinne, Mikael L.
- Borate, Uma
- Brunner, Andrew M.
- Titel
- Poster: MDS-420: Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study
- Ist Teil von
- Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S230-S230
- Ort / Verlag
- Elsevier Inc
- Erscheinungsjahr
- 2021
- Quelle
- Access via ScienceDirect (Elsevier)
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2152-2650eISSN: 2152-2669DOI: 10.1016/S2152-2650(21)01447-6Titel-ID: cdi_crossref_primary_10_1016_S2152_2650_21_01447_6
- Format
- –